A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

This study has been completed.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
First received: May 17, 2010
Last updated: May 24, 2010
Last verified: May 2010

This study is to compare its pharmacokinetics profile of two YM150 formulations by 2x2 crossover method.

Condition Intervention Phase
Healthy Volunteer
Pharmacokinetics of YM150
Drug: YM150
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B -

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Plasma concentration of YM150 and its metabolites measured by blood sample [ Time Frame: for 3 days after drug administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety assessed by AEs, vital signs, 12-lead ECG and lab tests [ Time Frame: or 3 days after drug administration ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: February 2010
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: formualation-A to -B sequence group Drug: YM150
Experimental: formulation-B to -A sequence group Drug: YM150


Ages Eligible for Study:   20 Years to 44 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body weight: ≥50.0 kg, <80.0 kg
  • BMI: ≥17.6, <26.4
  • Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and lab tests

Exclusion Criteria:

  • Received any investigational drugs within 120 days before the study
  • Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the study
  • Received medication within 7 days before the study
  • A deviation from the assessment criteria of physical examinations or laboratory tests
  • A deviation from the normal reference range of coagulation test [PT (INR) or aPTT]
  • History of drug allergies
  • Upper gastrointestinal disease within 7 days before the study
  • Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases
  • Concurrent or previous malignant tumor
  • Previous treatment with YM150
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01125657

Kyushu, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

No publications provided

Responsible Party: Director, Astellas Pharma, Inc
ClinicalTrials.gov Identifier: NCT01125657     History of Changes
Other Study ID Numbers: 150-CL-046
Study First Received: May 17, 2010
Last Updated: May 24, 2010
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Astellas Pharma Inc:
bioequivalence study

ClinicalTrials.gov processed this record on April 23, 2014